Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Stockholm - Delayed Quote SEK

Cereno Scientific AB (publ) (CRNO-B.ST)

8.00
+0.03
+(0.38%)
At close: April 25 at 5:29:38 PM GMT+2

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
NameTitlePayExercisedYear Born
Mr. Sten R. Sorensen CEO & Director 7.35M -- 1959
Mr. Jonas Faijerson Saljo Chief Intellectual Property Officer 893k -- 1977
Ms. Eva Jagenheim Chief Financial Officer -- -- 1966
Dr. Bjorn Dahlof FACC, FESC, M.D., Ph.D. Chief Scientific Officer 96k -- 1953
Ms. Tove Bergenholt Head of IR & Communications -- -- 1988
Mr. Fredrik Frick Head of Clinical Operations -- -- 1973
Mr. Nicholas Oakes Head of Preclinical Development -- -- 1961
Dr. Rahul Agrawal M.D. Chief Medical Officer & Head of R&D -- -- 1965

Cereno Scientific AB (publ)

BioVentureHub
Pepparedsleden 1 MOelndal
Gothenburg, 431 83
Sweden
46 768 66 77 87 https://www.cerenoscientific.com
Sector: 
Healthcare

Description

Cereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide. The company's lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and antithrombotic properties. Its preclinical drug candidates comprise CS585 and CS014 that is in pre clinical stage for the treatment of cardiovascular diseases. The company has a collaboration agreement with the University of Michigan for the preclinical development program of CS585 and CS014, are preclinical drug candidate for cardiovascular diseases; and Abbott for use of CardioMEMS HF System, as well as collaboration with the Pulmonary and Vascular Research Institute (PVRI). Cereno Scientific AB (publ) was incorporated in 2012 and is headquartered in Gothenburg, Sweden.

Corporate Governance

Cereno Scientific AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 22, 2025 at 10:59 AM UTC

Cereno Scientific AB (publ) Earnings Date

Recent Events

Related Tickers

ODI.ST ODI Pharma AB
2.5800
0.00%
 
SLNX Solanbridge Group, Inc.
0.0000
0.00%
 
MOB.ST Moberg Pharma AB (publ)
8.11
+2.47%
 
GSAC GelStat Corp.
0.0004
0.00%
 
RIPP.CN Digital Commodities Capital Corp.
0.0400
-20.00%
 
SHPH Shuttle Pharmaceuticals Holdings, Inc.
0.3100
+4.52%
 
UPC Universe Pharmaceuticals INC
4.2000
+10.53%
 
ELTP Elite Pharmaceuticals, Inc.
0.4200
+0.02%
 
GELS Gelteq Limited
1.9000
-18.10%
 
PTPI Petros Pharmaceuticals, Inc.
0.0540
+5.47%